Cargando…

Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availability

In β‐thalassaemia, anaemia results from ineffective erythropoiesis characterized by inhibition of late‐stage erythroid differentiation. We earlier used luspatercept and RAP‐536 protein traps for certain Smad2/3‐pathway ligands to implicate Smad2/3‐pathway overactivation in dysregulated erythroid dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez, Pedro A., Li, Robert, Ramanathan, Harish N., Bhasin, Manoj, Pearsall, R. Scott, Kumar, Ravindra, Suragani, Rajasekhar N. V. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294138/ https://www.ncbi.nlm.nih.gov/pubmed/32351032 http://dx.doi.org/10.1111/jcmm.15243

Ejemplares similares

Functionally diverse heteromeric traps for ligands of the transforming growth factor-β superfamily
por: Kumar, Ravindra, et al.
Publicado: (2021)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease
por: Pearsall, R. S., et al.
Publicado: (2019)

Dynamics of GATA1 binding and expression response in a GATA1-induced erythroid differentiation system
por: Jain, Deepti, et al.
Publicado: (2015)

5610224 THE USE OF LUSPATERCEPT IN PATIENTS WITH β -THALASSAEMIA AND MULTIPLE SYSTEMIC COMPLICATIONS INCREASES HEMOGLOBIN LEVEL, DECREASES TRANSFUSION BURDEN, AND IS UNAFFECTED BY COMPLICATIONS. SINGLE THALASSEMIA AND SICKLE CELL DEPARTEMENT’S EXPERIENCE.
por: Manganas, K.M., et al.
Publicado: (2023)

Impaired neutrophil extracellular trap formation in β-thalassaemia/HbE
por: Thubthed, Rattanawan, et al.
Publicado: (2022)

TP53 Modulates Oxidative Stress in Gata1(+) Erythroid Cells
por: Kramer, Ashley C., et al.
Publicado: (2017)

FAM122A Inhibits Erythroid Differentiation through GATA1
por: Chen, Jing, et al.
Publicado: (2020)

Gata1s mutant mice display persistent defects in the erythroid lineage
por: Ling, Te, et al.
Publicado: (2022)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

α-thalassaemia
por: Harteveld, Cornelis L, et al.
Publicado: (2010)

FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors
por: Mancini, Elena, et al.
Publicado: (2012)

Histone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiation
por: Guo, Yidi, et al.
Publicado: (2015)

Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1
por: Liang, Long, et al.
Publicado: (2019)

C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor
por: Di Genua, Cristina, et al.
Publicado: (2020)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

GATA1 and PU.1 Bind to Ribosomal Protein Genes in Erythroid Cells: Implications for Ribosomopathies
por: Amanatiadou, Elsa P., et al.
Publicado: (2015)

Intron 1 GATA site enhances ALAS2 expression indispensably during erythroid differentiation
por: Zhang, Yingchi, et al.
Publicado: (2017)

Thalassaemia Intermedia: an Update
por: Taher, Ali T., et al.
Publicado: (2009)

Screening for beta thalassaemia
por: Petrou, Mary
Publicado: (2010)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Thalassaemia and Aberrations of Growth and Puberty
por: Kyriakou, Andreas, et al.
Publicado: (2009)

THALASSAEMIA IS A TROPICAL DISEASE
por: Kotila, T.R.
Publicado: (2012)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
por: Marchand, Alexandre, et al.
Publicado: (2022)

hGATA1 Under the Control of a μLCR/β-Globin Promoter Rescues the Erythroid but Not the Megakaryocytic Phenotype Induced by the Gata1 ( low ) Mutation in Mice
por: Martelli, Fabrizio, et al.
Publicado: (2021)

Observational study on the current status of thalassaemia in Malaysia: a report from the Malaysian Thalassaemia Registry
por: Mohd Ibrahim, Hishamshah, et al.
Publicado: (2020)

The leukemia associated ETO nuclear repressor gene is regulated by the GATA-1 transcription factor in erythroid/megakaryocytic cells
por: Ajore, Ram, et al.
Publicado: (2010)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
por: Viprakasit, V., et al.
Publicado: (2022)

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7bggs1cpgvatlsr148c9ok79er